ADVANCED TECHNOLOGY FOR ASSAYING CANCER-DRUG RESISTANCE

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$183,926.00
Award Year:
2005
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA114126-01
Award Id:
75478
Agency Tracking Number:
CA114126
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Ambergen, Inc. (Currently AMBERGEN, INC)
Ambergen, Inc., 100 Beaver Street, Waltham, MA, 02453
Hubzone Owned:
N
Minority Owned:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
MARK LIM
(617) 975-0689
MARK_LIM@AMBERGEN.COM
Business Contact:
NORMAN PRIEBATSCH
(781) 419-4055
NEP@AMBERGEN.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Significant advances have been made in the development of a new generation of molecularly targeted cancer drugs, many of which are only now emerging from the drug development pipeline. Examples of small molecule drugs are imatinib (Gleevec), used to treat CML, and gefinitib (Iressa), used to treat lung cancer. Other drugs, such as cetuximab (Erbitux) for colorectal cancer, are monoclonal antibodies. All of these drugs selectively modulate the activity of specific target proteins such as BCR-ABL tyrosine kinase (imatinib) and EGFR (gefitinib and cetuximab) that are critical for the proliferation and survival of cancer cells. However, clinical studies are revealing that patients often develop drug resistance due to overproduction or mutant forms of the target protein. For this reason, it is likely that future treatment with single or multiple targeted cancer drugs will require testing for preexisting or acquired resistance at the level of the target protein. The principal objective of this proposal is to develop and evaluate a sensitive and low cost technology known as PC-SNAG for monitoring resistance, to one or more drugs, in patients at the level of individual target proteins. A key feature of PC-SNAG is the ability to rapidly isolate native/active proteins from crude biological samples using photocleavable antibodies (PC-antibodies). During Phase I, proprietary high efficiency photocleavable linkers will be used to produce PC-antibodies immobilized on beads or other solid surfaces. The PC-antibodies are used to isolate and concentrate the target proteins from a heterogeneous biological sample. The target protein is then rapidly and gently photo released into solution in a native and highly pure form for functional analyses in the presence of drug. PC-SNAG facilitates a number of high throughput, sensitive functional assays that will be evaluated to detect resistant forms of the drug target and to determine optimal drug therapy on a per patient basis. In Phase I, the technology will be tested using model kinase-directed small molecule and antibody drugs followed by a focus on detection of drug resistant forms of the BCR-ABL tyrosine kinase. One goal is detection of <5% of the resistant form of the target, which is difficult to achieve using conventional DNA sequencing. In Phase II, clinical evaluation of the technology will be performed in collaboration with Dr. Daniel Wright, Chief of Hematology/Oncology at the Boston University Medical Center.

* information listed above is at the time of submission.

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government